

10/634,473

2

PC25243A

REMARKS

Claims 1-12 are pending.

Elections/Restrictions

In the Office Action, restriction under 35 U.S.C. § 121 was required. Applicants hereby elect without traverse the invention of Group III, claims 1-12 drawn to a compound of formula I, wherein Y is CH₂, C(=O), C(H)(R⁷), or C(R⁷)₂, a composition, and a method of use; which invention was classified in class 546, subclasses 140, 141, 142, and others, class 514, subclasses 307, 308, 309, 310, and others depending upon the preferred embodiments of other heterocyclic or heteroaryl groups.

Claims 1-12 read on the invention of Group III. Applicants also elect under 35 U.S.C. § 121 the single disclosed species 1-oxo-2-[4-(2H-tetrazol-5-yl)-benzyl]-1,2-dihydro-isoquinoline-7-carboxylic acid 3-methoxy-benzylamide, which is the fourth species of claim 8 and the compound of Example 59.

Conclusion

In view of the above remarks, Applicants believe that the restriction requirements for claims 1-12 are met, and request consideration of the elected invention of Group III in claims 1-12.

Respectfully submitted,

Date: September 19, 2005

Claude F. Purchase, Jr.

Claude F. Purchase, Jr.
Reg. No. 47,871
Pfizer Inc.
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-1692
Fax (734) 622-1553